NCT02980705

Efficacy and Safety Study of SUNPG1622

A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Sun Pharmaceutical Industries Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.

Conditions

• Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

Interventions

Type	Name	Description
DRUG	SUNPG1622 I dose	Injection
DRUG	Placebo dose	Injection

Timeline

• Start date: 2017-11-06
• Primary completion: 2019-02-21
• Completion: 2019-09-03
• First posted: 2016-12-02
• Last updated: 2021-11-01
• Results posted: 2021-02-21

Locations

4 sites across 4 countries: United States, Hungary, Poland, Spain

Regulatory

• FDA-regulated drug study